Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of MucostaⓇ (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis. Methods: This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or MucostaⓇ thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; MucostaⓇ, n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; MucostaⓇ, n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated. Results: According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and MucostaⓇ-treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and MucostaⓇ-treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was −4.01% (95% confidence interval [CI], –13.09% to 5.06%) in the ITT analysis and −4.44% (95% CI, –13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 MucostaⓇ-treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates. Conclusions: The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (MucostaⓇ) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis.
Abstract
Background/Aims: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of MucostaⓇ (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis. Methods: This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or MucostaⓇ thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; MucostaⓇ, n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; MucostaⓇ, n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated. Results: According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and MucostaⓇ-treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and MucostaⓇ-treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was −4.01% (95% confidence interval [CI], –13.09% to 5.06%) in the ITT analysis and −4.44% (95% CI, –13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 MucostaⓇ-treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates. Conclusions: The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (MucostaⓇ) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis.
참고문헌 (29)
- Laine L, "Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers", Gastrointest Endosc, 42, pp.420~423 (1995)
- Park HK, "The distribution of endoscopic gastritis in 25, 536 heath check-up subjects in Korea", Korean J Helicobacter Up Gastrointest Res, 12, pp.237~243 (2012)
- Yoshikazu Kinoshita, "Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use", Journal of Neurogastroenterology and Motility (JNM), 24(2), pp.182~196 (2018), 대한소화기 기능성질환∙운동학회[DOI]
- Jalving M, "Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy", Aliment Pharmacol Ther, 24, pp.1341~1348 (2006)
- Raghunath AS, "Review article : the long-term use of proton-pump inhibitors", Aliment Pharmacol Ther, 22(Suppl 1), pp.55~63 (2005)
- 김광하, "Proton Pump Inhibitor-Related Gastric Mucosal Changes", Gut and Liver, 15(5), pp.646~652 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- García Rodríguez LA, "Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma : a nested case control study in the UK", Gut, 55, pp.1538~1544 (2006)
- Waldum HL, "Proton pump inhibitors(PPIs)may cause gastric cancer : clinical consequences", Scand J Gastroenterol, 53, pp.639~642 (2018)
- Du Y, "Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis : a randomized sucralfatecontrolled multicenter trial in China-STARS study", Dig Dis Sci, 53, pp.2886~2895 (2008)
- Chitapanarux T, "An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors", Dig Dis Sci, 53, pp.2896~2903 (2008)
- Han X, "Effect of rebamipide on the premalignant progression of chronic gastritis : a randomized controlled study", Clin Drug Investig, 35, pp.665~673 (2015)
- Arakawa T, "15th anniversary of rebamipide : looking ahead to the new mechanisms and new applications", Dig Dis Sci, 50(Suppl 1), pp.S3~S11 (2005)
- Naito Y, "Rebamipide : a gastrointestinal protective drug with pleiotropic activities", Expert Rev Gastroenterol Hepatol, 4, pp.261~270 (2010)
- Hasegawa S, "Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers", Clin Drug Investig, 23, pp.771~779 (2003)
- Seol SY, "DA9601 for erosive gastritis : results of a double-blind placebocontrolled phase III clinical trial", World J Gastroenterol, 10, pp.2379~2382 (2004)
- 심기남, "The efficacy and safety of irsogladine maleate in nonsteroidal anti-inflammatory drug or aspirin-induced peptic ulcer and gastritis", The Korean Journal of Internal Medicine, 34(5), pp.1008~1021 (2019), 대한내과학회[DOI]
- 정정조, "위염 환자에서 글립타이드？정(Sulglycotide 200 mg)의 치료 효과를 평가하기 위한 단일맹검, 무작위 배정, 비교약 대조, 다기관 임상시험", Clinical Endoscopy, 35(3), pp.125~132 (2007), 대한소화기내시경학회
- 최윤진, "Evaluation of the Efficacy and Safety of DA-9601 versus Its New Formulation, DA-5204, in Patients with Gastritis: Phase III, Randomized, Double-Blind, Non-Inferiority Study", Journal of Korean Medical Science, 32(11), pp.1807~1818 (2017), 대한의학회
- 한혜원, "미란성 위염에 대한 알비스^Ⓡ의 효과: 스티렌^Ⓡ 대조 무작위 이중맹검 다기관 임상시험", Clinical Endoscopy, 42(4), pp.215~221 (2011), 대한소화기내시경학회
- Syam AF, "Molecular mechanism on healing process of peptic ulcer", Acta Med Indones, 41, pp.95~98 (2009)
- Risau W, "Mechanisms of angiogenesis", Nature, 386, pp.671~674 (1997)
- Tarnawski A, "Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats:one mechanism for its ulcer healing action?", Dig Dis Sci, 43(9 Suppl), pp.90S~98S (1998)
- Haruma K, "Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis", Dig Dis Sci, 47, pp.862~867 (2002)
- Kamada T, "Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication : a multicenter study", Biomed Res Int, 2015, pp.865146~ (2015)
- Kim HK, "Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers", Dig Dis Sci, 52, pp.1776~1782 (2007)
- Miwa H, "Effect of a gastroprotective agent, rebamipide, on symptom improvement in patients with functional dyspepsia : a double-blind placebo-controlled study in Japan", J Gastroenterol Hepatol, 21, pp.1826~1831 (2006)
- Claxton AJ, "A systematic review of the associations between dose regimens and medication compliance", Clin Ther, 23, pp.1296~1310 (2001)
- Garfinkel D, "Feasibility study of a systematic approach for discontinuation of multiple medications in older adults : addressing polypharmacy", Arch Intern Med, 170, pp.1648~1654 (2010)
- Toh MR, "Association between number of doses per day, number of medications and patient's non-compliance, and frequency of readmissions in a multi-ethnic Asian population", Prev Med Rep, 1, pp.43~47 (2014)